Back to Journals » Clinical Interventions in Aging » Volume 7

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease

Authors Hametner E, Seppi K, Poewe W

Received 19 September 2011

Accepted for publication 26 October 2011

Published 15 March 2012 Volume 2012:7 Pages 83—88


Review by Single anonymous peer review

Peer reviewer comments 3

Eva-Maria Hametner, Klaus Seppi, Werner Poewe

Department of Neurology, Innsbruck Medical University, Innsbruck, Austria

Abstract: The aim of this article is to provide a short review of the most relevant pharmacological and clinical data on pramipexole extended release (ER) as well as to address the clinical utility and potential advantages of a once-daily formulation especially in the treatment of early Parkinson's disease (PD). Pramipexole is widely established as a symptomatic treatment in early as well as advanced PD. The development of an ER formulation, with stable pramipexole plasma concentration over 24 hours, now offers a bioequivalent once-daily alternative. Double-blind randomized controlled trials in early and advanced PD, have established noninferiority of pramipexole ER compared with immediate release as well as superiority of both formulations over placebo. The overnight switch from the standard to the once-daily formulation was shown to be successful in >80% of patients without requiring any dose adjustments. Potential benefits of the prolonged-release design, which have not yet been formally demonstrated in the pivotal trial program, include improved compliance and a potential for better symptomatic control, particularly in patients with early disease that can be managed with monotherapy.

Keywords: pramipexole, Parkinson's disease, extended release, compliance, control

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.